WEBULL

Assessing Tyra Biosciences (TYRA) Valuation Following Key Executive Hires to Support Advancing Clinical Pipeline

Simply Wall St · 2d ago

Tyra Biosciences (TYRA) just reshuffled its leadership bench, bringing in regulatory veteran Heather Faulds as Chief Regulatory Officer and commercial operator Bhavesh Ashar as Chief Operating Officer to help steer its advancing clinical pipeline.

See our latest analysis for Tyra Biosciences.

Those hires land as Tyra’s share price has climbed to $22.63, with a 30 day share price return of 43.87 percent and a three year total shareholder return of 222.36 percent, which signals strong and building momentum around its pipeline story.

If this kind of clinical stage momentum interests you, it might be worth exploring other innovative names in healthcare stocks to see what else fits your strategy.

Yet despite hefty recent gains, Tyra still trades roughly 40 percent below consensus targets. This raises a key question for investors: Is there meaningful upside left here, or has the market already priced in tomorrow’s growth?

Price to Book of 4.3x, Is it justified?

Tyra Biosciences last closed at $22.63, and its 4.3x price to book ratio points to a rich valuation compared to the wider US biotech space.

The price to book ratio compares a company’s market value with its net assets, a useful lens for early stage, loss making biotech names where earnings are not yet meaningful.

For Tyra, that 4.3x figure looks demanding next to the broader US Biotechs industry at 2.7x. This suggests investors are paying a premium relative to typical asset backing, even though the company is still unprofitable and forecast to remain so for at least three years.

However, when stacked against its closer peer group, Tyra’s 4.3x multiple sits well below the 10.9x average. This implies that while it trades at a sector premium, it may still offer comparatively better value than similar high growth, clinical stage peers that command much higher balance sheet multiples.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book of 4.3x (ABOUT RIGHT)

However, setbacks in TYRA-300 or TYRA-200 trials, or dilution from future capital raises, could quickly temper the enthusiasm baked into today’s valuation.

Find out about the key risks to this Tyra Biosciences narrative.

Build Your Own Tyra Biosciences Narrative

If you see the story differently or want to review the numbers yourself, you can quickly build a personalized view of Tyra using Do it your way.

A great starting point for your Tyra Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Before you move on, consider your next step by scanning fresh opportunities on the Simply Wall St Screener so that potential candidates do not pass you by.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.